- Home
- AVNT vs MRUS Comparison
AVNT vs MRUS Comparison
Compare AVNT & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AVNT
- MRUS
- Stock Information
- Founded
- AVNT 1927
- MRUS 2003
- Country
- AVNT United States
- MRUS Netherlands
- Employees
- AVNT N/A
- MRUS N/A
- Industry
- AVNT Major Chemicals
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- AVNT Industrials
- MRUS Health Care
- Exchange
- AVNT Nasdaq
- MRUS Nasdaq
- Market Cap
- AVNT 3.4B
- MRUS 2.7B
- IPO Year
- AVNT 1993
- MRUS 2016
- Fundamental
- Price
- AVNT $32.52
- MRUS $41.73
- Analyst Decision
- AVNT Strong Buy
- MRUS Strong Buy
- Analyst Count
- AVNT 5
- MRUS 13
- Target Price
- AVNT $54.40
- MRUS $86.85
- AVG Volume (30 Days)
- AVNT 667.9K
- MRUS 716.9K
- Earning Date
- AVNT 05-06-2025
- MRUS 05-07-2025
- Dividend Yield
- AVNT 3.30%
- MRUS N/A
- EPS Growth
- AVNT 121.98
- MRUS N/A
- EPS
- AVNT 1.84
- MRUS N/A
- Revenue
- AVNT $3,240,400,000.00
- MRUS $36,133,000.00
- Revenue This Year
- AVNT $3.54
- MRUS $37.72
- Revenue Next Year
- AVNT $4.50
- MRUS $48.47
- P/E Ratio
- AVNT $20.58
- MRUS N/A
- Revenue Growth
- AVNT 3.11
- MRUS N/A
- 52 Week Low
- AVNT $32.48
- MRUS $37.77
- 52 Week High
- AVNT $54.68
- MRUS $61.61
- Technical
- Relative Strength Index (RSI)
- AVNT 24.46
- MRUS 41.48
- Support Level
- AVNT $36.01
- MRUS $38.40
- Resistance Level
- AVNT $37.97
- MRUS $45.44
- Average True Range (ATR)
- AVNT 1.28
- MRUS 2.59
- MACD
- AVNT -0.47
- MRUS -0.79
- Stochastic Oscillator
- AVNT 0.29
- MRUS 29.21
About AVNT Avient Corporation
Avient Corp manufactures and sells various chemical and plastic-based products to designers and plastic processors. The firm operates in two segments: Color, Additives and Inks, and Specialty Engineered Materials. The company's product portfolio includes concentrated color and ink blends, plastic resins, and various specialized polymer materials used in industries such as food packaging, construction, transportation, cosmetics, and healthcare. The color, additives, & ink segment and the distribution segment together generate a vast majority of revenue. More than half of the total revenue is derived from the United States.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.